Shopping Cart
- Remove All
Your shopping cart is currently empty
CIQ is a subunit-selective potentiator of NMDA receptors containing the NR2C or NR2D subunit, with EC50 values of 2.7 μM for NR2C and 2.8 μM for NR2D.

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 2 mg | $29 | In Stock | |
| 5 mg | $46 | In Stock | |
| 10 mg | $76 | In Stock | |
| 25 mg | $148 | In Stock | |
| 50 mg | $221 | In Stock | |
| 100 mg | $326 | In Stock | |
| 1 mL x 10 mM (in DMSO) | $49 | In Stock |
| Description | CIQ is a subunit-selective potentiator of NMDA receptors containing the NR2C or NR2D subunit, with EC50 values of 2.7 μM for NR2C and 2.8 μM for NR2D. |
| Targets&IC50 | NR2C:2.7 μM(EC50), NR2D:2.8 μM(EC50) |
| In vitro | CIQ reduces associated behaviours in schizophrenia models and potentially enhances dopamine release in Parkinson's disease models. NMDA receptor CIQ increases channel opening frequency of recombinant NR2Cor NR2D containing receptors by two-fold (EC50 = 2.7 and 2.8 μM, respectively). It has no effect on NR2A or NR2B subtypes. CIQ does not alter the EC50 values for glutamate or glycine on channel opening. CIQ increases channel opening efficiency and enhances NMDA receptor responses. |
| Molecular Weight | 467.94 |
| Formula | C26H26ClNO5 |
| Cas No. | 486427-17-2 |
| Smiles | COc1ccc(OCC2N(CCc3cc(OC)c(OC)cc23)C(=O)c2cccc(Cl)c2)cc1 |
| Relative Density. | 1.238 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 50 mg/mL (106.85 mM), Sonication is recommended. H2O: insoluble | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (4.27 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.